Phlegm

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

The shame and pleasure of masturbation: Poor Things gets girls’ early sexual feelings right

Retrieved on: 
Tuesday, January 16, 2024

Yorgos Lanthimos’ film follows Bella Baxter (Emma Stone), a scientist’s experiment created from a woman’s body and a child’s mind.

Key Points: 
  • Yorgos Lanthimos’ film follows Bella Baxter (Emma Stone), a scientist’s experiment created from a woman’s body and a child’s mind.
  • But I think it is wrong to read Poor Things as a film about grown women.
  • It accurately depicts girls’ early sexual feelings and shows us some more positive ways of understanding girlhood sexual desire.

Discovering sexuality

  • Early in the film, Bella teaches herself to masturbate and is delighted by her discovery.
  • Many of my interviewees had similar memories, often describing themselves as “exploring” their bodies and finding enjoyable sensations in the process.
  • Interviewees, including Nicole, were normally aged between five and 10 during these experiences (which are normal and common among children).
  • Interviewees regularly described their early forays into masturbation as disconnected from adult sexuality.

Girls are interested in sex


In the recent past, the media depicted boys as much more sexual than girls, who were supposedly interested in romance instead. Even magazines like Dolly – which catered to girls and spoke openly about sex – assumed girls’ sexual impulses would be awakened by their boyfriends’ advances.

  • This is clear even in well-meaning advice to girls about not being “pressured” into sex, which presupposes girls would not initiate sex themselves.
  • She concluded:
    obviously you’re not meant to have fun like that […] obviously you’re not meant to do it yourself.
  • obviously you’re not meant to have fun like that […] obviously you’re not meant to do it yourself.

A healthy sexuality

  • Several interviewees told me they learned the word “masturbation” from Dolly, which portrayed it as a normal and healthy practice.
  • “Oh, that’s what I’ve been doing”, thought Nicole when she found instructions on how to masturbate in the magazine.
  • She develops a healthy relationship to her sexuality; she knows sex should be enjoyable for her, not just for men, and that she should not be coerced into it.
  • We can show future generations there is nothing shameful about sexuality.
  • Read more:
    Poor Things: meet the radical Scottish visionary behind the new hit film

    *Names have been changed.


Saskia Roberts does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Achieve Peak Wellness with SANESolution's Doctor-Endorsed Throat Cleaner

Retrieved on: 
Saturday, September 9, 2023

BELLEVUE, Wash., Sept. 9, 2023 /PRNewswire-PRWeb/ -- SANESolution, a leading provider of cutting-edge health solutions, is excited to announce the unveiling of its brand-new website, https://throatcleaner.com/. This platform will serve as a comprehensive hub for showcasing the company's groundbreaking product, SANE Vitaae® - a doctor-formulated throat-cleaning supplement designed to support the body's natural ability to combat throat phlegm.

Key Points: 
  • Vitaae is a natural solution to help combat throat phlegm caused by allergies, chronic cough, and other conditions in a safe and effective manner.
  • This revolutionary throat-cleaning formula helps the body naturally soothe the neurological inflammation often responsible for such reactions.
  • According to the most recent revolutionary studies, it may have significant ties to obesity, persistent cough, excess throat phlegm, and potentially cardiovascular disease."
  • For more information or to purchase Vitaae® visit the new throat cleaner website: https://throatcleaner.com/

My child has a cough, so what's wrong with using cough syrup?

Retrieved on: 
Monday, May 15, 2023

In previous generations, parents might have reached for the cough syrup to relieve a dry or chesty cough.

Key Points: 
  • In previous generations, parents might have reached for the cough syrup to relieve a dry or chesty cough.
  • And amid mounting evidence of harms from poisoning and deaths, many countries including Australia have restricted cough medicines so they can’t be given to children aged under six.

What’s in cough medicine?

    • They can contain cough suppressants (dampening the body’s cough reflex), expectorants and mucolytics (both of which help clear phlegm).
    • Read more:
      Health Check: why do I have a cough and what can I do about it?
    • The riskiest medications are those with a sedative action, such as sedating antihistamines or opioid-based cough suppressants.

How are cough syrups restricted?

    • Young children under two years old are most at risk of a fatal overdose from cough syrups.
    • But Australia’s drug regulator recommends against using cough syrups for anyone under six years of age.
    • Cough syrups are still available for older children and adults.

When is it OK to use cough syrups?

    • Cough syrups can be used for in children aged six to 11 years, however caution is still needed.
    • Unfortunately, there is no convincing evidence these medications meaningfully improve cough symptoms.
    • Simple syrups containing no medication can also be effective: up to 85% of the effectiveness of cough medicines has been put down to the “placebo effect”.

So what can I do for my kid?

    • Paracetamol or ibuprofen can be used if they have fever, aches and pains along with their cough.
    • If your child is older than 12 months and has a wet cough (producing phlegm in their throat), consider giving them honey.
    • She is also the recipient of an untied educational grant from Reckitt to fund a PhD stipend into over-the-counter analgesic research.

argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

The presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases.

Key Points: 
  • The presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases.
  • Long-term treatment, administered in individualized dosing cycles, led to consistent and repeatable reductions in IgG antibody levels and improved clinical outcomes.
  • A cross-indication review of the safety profile of efgartigimod will also be presented across multiple IgG-mediated autoimmune diseases, reinforcing the consistent safety profile observed with efgartigimod.
  • Your health care provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART.

Pulmonary Drug Delivery Systems Market Report 2022: Featuring Abbott, Dr. Reddy's Laboratories, GlaxoSmithKline, Lupin and Pfizer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022

The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis.
  • Pulmonary drug delivery is an alternative to oral drug delivery.
  • The market for pulmonary drug delivery systems is growing rapidly due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses.

World COPD Day: Lung Association Launches Campaign to Improve Care for 12.5 million Americans Living with COPD

Retrieved on: 
Wednesday, November 16, 2022

CHICAGO, Nov. 16, 2022 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death in the United States. More than 12.5 million people have been diagnosed with COPD, but millions more may have the disease without even knowing it. Today, on World COPD Day, the American Lung Association aims to increase awareness about COPD, including the critical need to improve screening, early diagnosis and the quality of life for people living with the disease.

Key Points: 
  • More than 12.5 million people have been diagnosed with COPD, but millions more may have the disease without even knowing it.
  • Today, on World COPD Day, the American Lung Association aims to increase awareness about COPD , including thecritical need to improve screening, early diagnosis and the quality of life for people living with the disease.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that gets worse over time.
  • The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Global Chronic Obstructive Pulmonary Disease Treatment Devices Report to 2027 - Market Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022

The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027.
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:
    The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals.
  • Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M

Retrieved on: 
Wednesday, September 28, 2022

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.

Key Points: 
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.
  • Investors participating in bioAffinity Technologies financing exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and 310,910 non-tradable warrants at a price of $7.656 per share.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of common shares.

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE

Retrieved on: 
Wednesday, September 14, 2022

The journal PLOS ONE , published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung.

Key Points: 
  • The journal PLOS ONE , published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung.
  • The PLOS ONE paper presents our unique method for determining the health of an individuals lungs, bioAffinity President and CEO Maria Zannes said.
  • Flow cytometry allows for analysis of whole cells and cell populations that make up the lung environment.
  • bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.